Masimo (NASDAQ:MASI) Corporation (NASDAQ:MASI), a medical technology company, has announced the termination of its Chief Executive Officer, Joe Kiani, effective October 24, 2024. The decision was made by the Board of Directors following a review by outside counsel. Concurrently, Michelle Brennan has been appointed as the Interim Chief Executive Officer.
The Irvine, California-based company, which specializes in electromedical and electrotherapeutic apparatus, reaffirmed its non-GAAP financial guidance for the third quarter and full fiscal year of 2024, maintaining the projections set forth on August 6, 2024, and reaffirmed on September 25, 2024. This includes revenue guidance for the healthcare segment. Additionally, the company is exploring strategic alternatives for its consumer segment.
The announcement was made in a regulatory filing with the Securities and Exchange Commission on Tuesday. As per the filing, the information disclosed under Item 2.02 regarding the company's financial condition shall not be deemed "filed" for legal purposes and will not be incorporated into any future filings under the Securities Act of 1933 or the Securities Exchange Act of 1934.
Masimo's shares are publicly traded on The Nasdaq Stock Market under the ticker symbol MASI. The company has not disclosed the reasons for Kiani's departure or the details of the strategic alternatives being considered for the consumer segment.
The news of Kiani's termination and the reaffirmation of financial guidance may be of interest to investors and stakeholders who follow the company's performance and leadership changes. The company's business address is 52 Discovery (NASDAQ:WBD), Irvine, CA 92618, and it is incorporated in Delaware.
In other recent news, Apple Inc (NASDAQ:AAPL). has secured a victory in a patent case against Masimo Corporation. A federal jury awarded Apple a nominal $250 in damages after finding that Masimo infringed on two of Apple's design patents with its earlier versions of smartwatches and chargers. However, the jury ruled that Masimo's current smartwatch models do not infringe on Apple's patents.
In parallel, Masimo has been maintaining its course amidst a flurry of developments. Piper Sandler has reiterated an Overweight rating on Masimo, emphasizing the potential for the company's stock to rise further. The firm's confidence stems from the expectation of an earnings power inflection in 2025 and 2026, which is seen as potentially outpacing any other stock within Piper Sandler's coverage universe.
Masimo also announced a significant change in its executive team, with CEO Joe Kiani stepping down and Michelle Brennan taking over as interim CEO. The company is maintaining its third-quarter non-GAAP financial guidance, projecting revenues between $495 million and $515 million, and earnings per share (EPS) forecast set at $0.81 to $0.86.
Lastly, Masimo is engaged in ongoing trade secrets litigation against Apple, with a bench trial set to start soon. Wells Fargo (NYSE:WFC) has reaffirmed its Overweight rating on Masimo shares, maintaining a price target of $160.00 despite these ongoing legal proceedings.
InvestingPro Insights
In light of Masimo Corporation's recent leadership change and reaffirmation of financial guidance, InvestingPro data provides additional context for investors. Despite the company's recent challenges, Masimo's market capitalization stands at $7.51 billion, reflecting its significant presence in the medical technology sector.
The company's financial health appears mixed. While Masimo's revenue for the last twelve months as of Q2 2024 was $2.02 billion, it experienced a revenue decline of 7.76% over the same period. However, the most recent quarterly revenue growth (Q2 2024) showed a positive trend at 9.01%, which aligns with the company's reaffirmed guidance.
InvestingPro Tips highlight that Masimo operates with a moderate level of debt and its liquid assets exceed short-term obligations, potentially providing stability during this transition period. The company has also demonstrated strong returns, with a 70.39% price total return over the past year and a 30.18% return over the last three months.
It's worth noting that Masimo is trading at high valuation multiples, including a P/E ratio of 93.76 and a Price / Book ratio of 5.51. This suggests that investors have high expectations for future growth, which the new leadership will need to deliver on.
For investors seeking a more comprehensive analysis, InvestingPro offers 13 additional tips for Masimo, providing a deeper understanding of the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.